Oral complications of cancer therapies: Prevention and management

Clinical Oncology

Volumn 8, Issue 1, 1996, Pages 15-24

  Singh, N ^a,b   Scully, C ^a   Joyston Bechal, S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANETHOLE TRITHIONE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZYDAMINE; CHLORHEXIDINE; LUBRICATING AGENT; PROSTAGLANDIN;

BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DENTAL CARE; HUMAN; MOUTH INFECTION; MOUTH ULCER; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; TASTE DISORDER; TOOTH DISEASE; XEROSTOMIA;

EID: 0029997214     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(05)80034-2     Document Type: Review

References (158)

1. Scully C. Management of the sore mouth. Eur J Palliat Care 1995, suppl 1:13-15.
2. Jansma J, Vissink A, Spijkervet FK, et al. Protocol for the prevention and treatment of oral sequelae resulting from head and neck radiation therapy. Cancer 1992;70:2171-80.
3. Toth BB, Martin JW, Fleming TJ. Oral complications associated with cancer therapy. J Clin Periodontol 1990;17:508-15.
4. Kolbinson DA, Schubert MM, Flournoy N, et al. Early oral changes following bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1988;66:130-8.
5. Carl W, Sako K. Cancer and the oral cavity. Chicago: Carol Stream, IL: Quintessence, 1986:167-83.
6. King GE, Scheetz J, Jacobs RF, et al. Electrotherapy and hyperbaric oxygen: Promising treatments for post-radiation complications. J Prosthet Dent 1989;62:331-4.
7. Carl W. Local radiation and systemic chemotherapy: Preventing and managing the oral complications. J Am Dent Assoc 1993;124:119-23.
8. Seto BG, Kim M, Wolinsky L, et al. Oral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1985;60:4493-7.
9. Dahllof G, Heimdahl A, Modeer T, et al. Oral mucous membrane lesions in children treated with bone marrow transplantation. Scand J Dent Res 1989;93:268-77.
10. Poland J. Prevention and treatment of oral complications in the cancer patient. Oncology 1991;5:45-62.
11. Ferretti GA, Ash RC, Brown AT, et al. Control of oral mucositis and candidiasis in marrow transplantation: A prospective double blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988;3:483-93.
12. Toth BB, Frame RT, Fleming TJ, et al. Dental oncology. Curr Probl Cancer 1983;7:7-35.
13. Borowski E, Benhamon E, Pico JL, et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomised controlled trial comparing two protocols of dental care. Eur J Cancer Oral Oncol 1994;30B:93-7.
14. Chapko MK, Syrjala KL, Schilter L, et al. Chemoradiotherapy toxicity during bone marrow transplantation: Time course and variation in pain and nausea. Bone Marrow Transplant 1989;4:181-6.
15. Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non head and neck malignancies. Oral Surg Oral Med Oral Pathol 1988;65:19-22.
16. Weisdorf DJ, Bostrom B, Raether D, et al. Oropharyngel mucositis complicating bone marrow transplantation: Prognostic factors and the effect of chlorhexidine mouth rinse. Bone Marrow Transplant 1989;4:89-95.
17. Carl W, Higby DJ. Oral manifestations of bone marrow transplantation. Am J Clin Oncol 1985;8:81-7.
18. Barret AP. A long-term prospective study of oral complications during conventional chemotherapy for acute leukemia. Oral Surg Oral Med Oral Pathol 1987;63:313-6.
19. Dreizen S, McCredie K, Bodey G, et al. Quantitative analysis of the oral complications of antileukemia chemotherapy. Oral Surg Oral Med Oral Pathol 1986;62:650-3.
20. Hickey AF, Toth BB, Lindqvist SB. Effect of intravenous hyperalimentation and oral care on the development of oral stomatitis during cancer chemotherapy. J Prosthet Dent 1982;47:188-93.
21. Marmary Y, Shiloni E, Katz J. Oral changes in interleukin-2 treated patients: A preliminary report, J Oral Pathol Med 1992;21:230-1.
22. McElroy TH. Infection in the patient receiving chemotherapy for cancer. J Am Dent Assoc 1984;109:454-6.
23. Carl W. Oral manifestations of systemic chemotherapy and their management. Semin Surg Oncol 1986;2:187-99.
24. Curtis JW, Caughman GB. An apparent unusual relationship between rampant caries and the oral mucosal manifestations of chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol 1994;78:267-72.
25. Stalman M, Purdell-Lewis DJ, Humphrey GB. Oral health in long-term survivors of childhood malignacies [abstract]. J Dent Res 1986;65:790.
26. Dreizen S. Description and incidence of oral complications. NCI Monogr 1990;9:11-5.
27. Jolly DE, Nag S. Technique for construction of dental moulds for high-dose-rate remote brachytherapy. Spec Care Dent 1992;12:219-24.
28. McHelroy H, Guerra O. Oral management of the head and neck radiation patient. Mo Med 1985;81:15-8.
29. Lockhart PB, Sonis ST. Alterations in the oral mucosa caused by chemotherapeutic agents. J Dermatol Surg 1981;7:1019-25.
30. Sonis ST, Costa JW, Evitts SM, et al. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1992;74:749-55.
31. Wahlin YB, Matsson L. Oral mucosal lesions in patients with acute leukemia and related disorders during cytotoxic therapy. Scand J Dent Res 1988;96:128-36.
32. Laine PO, Lindqvist JC, Pyrrhonen SO, et al. Lesions of the oral mucosa in lymophoma patients receiving cytotoxic drugs. Eur J Cancer Oral Oncol 1993;29B:291-4.
33. Dreizen S, McCredie K, Keating M, et al. Oral infections associated with chemotherapy in adult patients with acute leukemia. Postgrad Med 1982;71:133-45.
34. Periti P, Mazzei T. Infections in immunocompromised patients. II: Established therapy and its limitations. Clin Ther 1985;8:100-16.
35. Laine PO, Lindqvist JC, Pyrhonen SO, et al. Oral infections as a reason for febrile episodes in lymphoma patients receiving cytostatic drugs. Eur J Cancer Oral Oncol 1992;28B:103-7.
36. Archibald DJ, Sharman VM, Earle AS, et al. Oral complications of multimodality therapy for advanced squamous cell carcinoma of the head and neck cancer. Oral Surg Oral Med Oral Pathol 1986;61:139-41.
37. Lockhart PB, Clark JR. Oral complications following neoadjuvant chemotherapy in patients with head and neck cancer. NCI Monogr 1990;9:99-101.
38. Nikoskelainen J. Oral infections related to radiation and immunosuppressive therapy. J Clin Periodontaol 1990; 17:504-7.
39. Keane HJ, Fleming TJ, Toth BB. Cariogenic microflora in patients with Hodgkin's disease before and after mantle field radiotherapy. Oral Surg Oral Med Oral Pathol 1994;78:577-81.
40. O'Sullivan EA, Duggal MS, Bailey CC, et al. Changes in the oral microflora during cytotoxic chemotherapy in children being treated for acute leukemia. Oral Surg Oral Med Oral Pathol 1993;76:161-8.
41. Bergmann OJ. Oral infections and septicaemia in immunocompromised patients with haematologic malignancies. J Clin Microbiol 1988;26:2105-9.
42. Peterson D, Overholser C. Increased morbidity associated with oral infection in patients with acute nonlymphocytic leukemia. Oral Surg Oral Med Oral Pathol 1981;51:390-3.
43. Schimmpff S. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;30:13-20.
44. Schwartz R, Mackintosh R, Schrier S, et al. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984;53:411-9.
45. Bloomfield AL. The mechanism of elimination of bacteria in the respiratory tract. Am J Med Sci 1977;164:854-67.
46. Van Saene HKF, Martin MV. Do organisms play a role in irradiation mucositis? Eur J Clin Microbiol Infect Dis 1990;9:861-3.
47. Williams MC, Martin MV. A longitudinal study of the effects on the oral mucosa of treatment for acute childhood leukemia. Int J Paediatr Dent 1992;2:73-9.
48. Epstein JB, Marshall M, Le ND, et al. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993;76:169-74.
49. Working Party of the British Society for Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: A review of recommendations. J Antimicrob Chemother 1993;32:5-21.
50. Wade JC, Schimpff SC. Epidemiology and prevention of Candida infections. In: Bodey GP, Famstein V, editors. Candidosis. New York: Raven, 1985:111-3.
51. Martin MV, Al Tikriti U, Bromely PA. Yeast flora of the mouth and skin during and after irradiation for oral and laryngeal cancer. J Med Microbiol 1981;14:457-67,
52. Scully C, Samaranayake LP. Clinical virology in oral medicine and dentistry. Cambridge, Cambridge University Press, 1992.
53. Shannon IL, Trodahl JN, Starcke EN. Remineralisation of enamel by a saliva substitute designed for use by irradiated patients. Cancer 1978;41:1746-50.
54. Langdon J, Henk JM. Malignant tumours of the mouth, jaws and salivary glands. London: Edward Arnold, 1995.
55. Conger AD. Loss and recovery of taste acuity in patients irradiated to the oral cavity. Radiat Res 1973;53:338-47.
56. Carl W, Wood R. Effects of radiation on the developing dentition and supporting bone. J Am Dent Assoc 1980;101:646-8.
57. Dreizen S. Prevention of xerostomia-related dental caries in irradiated cancer patients. J Dent Res 1977;56:99-104.
58. Ritchie JR, Brown JR, Guerra LR, et al. Dental care for the irradiated cancer patient. Quintessence Int 1985;12:837-42.
59. Wright WE. Periodontium destruction associated with oncology therapy. Five case reports. J Periodontol 1987;58:559-63.
60. Murray CG, Herson J, Daly TE, et al. Radiation necrosis of the mandible: A 10-year study. Part 1: Factors influencing the onset of necrosis. Int J Radiat Oncol Biol Phys 1980;6:543-8.
61. Birchfield GR, Rodgers GM, Girodias KW, et al. Hypoprothrombinaema associated with interleukin-2 therapy: Correction with vitamin K. J Immunother 1992;11:71-5.
62. Richard V, Bernie M, Themelin L, etal. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). Ann Oncol 1991;2:67-8.
63. Epstein JB, Rea G, Wong FLW, et al. Osteonecrosis: A study of the relationship of dental extractions in patients receiving radiotherapy. Head Neck Surg 1987;10:48-54.
64. Bedwinek JM, Shukovsky LJ, Fletcher GH, et al. Osteonecrosis in patients treated with definitive radiotherapy for squamous cell carcinoma of the oral cavity and naso- and oropharynx. Radiology 1976;119:665-7.
65. Morris RB, Chan E, Silverman S, et al. Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer 1981;47:1980-3.
66. Murray CG, Herson J, Daly TE, et al. Radiation necrosis of the mandible: A 10-year study. Part 2: Dental factors; onset, duration and management of necrosis. Int J Radiat Oncol Biol Phys 1980;6:549-53.
67. Rankow RM, Weissman B. Osteonecrosis of the mandible. Ann Otol 1971;80:603-11.
68. Lockhart PB, Clark J. Pretherapy dental status of patients with malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1994;74:236-41.
69. Heimdahl A, Mattson T, Dahllof G, et al. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1989;68:711-6.
70. Tombes MB, Gallucci B. The effects of hydrogen peroxide rinses on the normal mucosa. Nurs Res 1993;42:332-7.
71. Ramp WK, Arnold RR, Russell JE, et al. Hydrogen peroxide inhibits glucose metabolism and collagen synthesis in bone. J Periodontal 1987;58:340-4.
72. Droge W, Schulze-Osthoff K, Mihm S, et al. functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J 1994;8:1131-8.
73. Mahmood N, Khan SG, Athar M, et al. Differential role of hydrogen peroxide and organic proxides in augmenting asbestos-mediated DNA damage: Implications for asbestos induced carcinogenesis. Biochem Biophys Res Commun 1994;200:687-94.
74. O'Reilly P, McCartan BE, Clancy J. Alcohol content of proprietary mouthwashes. Ir J Med Sci 1994;163:178-81.
75. Winn DM, Blot WJ, McLaughlin JK, et al. Mouthwash use and oral conditions in the risk of oral and pharyngeal cancer. Cancer Res 1991;51:3044-7.
76. Franco EM, Cury JA. Effect of Plax prebrushing rinse on enamel fluoride deposition. Am J Dent 1994;7:119-21,
77. Bhatti SA, Walsh TF, Douglas CW. Ethanol and pH levels of proprietary mouthrinses. Community Dent Health 1994;11:71-4.
78. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Int J Radiat Oncol Biol Phys 1986;62:145-8.
79. Matthews RW, Scully CM, Levers BG, et al. Clinical evaluation of benzydamine, chlorhexidine, and placebo mouthwashes in the management of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1987;63:189-91.
80. Barkvoll P, Attramadal A. Effect of nystatin and chlorhexidine digluconate on Candida albicans Oral Surg Oral Med Oral Pathol 1989;67:279-81.
81. Addy M, Roberts WR, Comparison of the bisbiguanide antiseptics alexidine and chlorhexidine: Clinical and in vitro staining properties. J Clin Periodontol 1981;8:220-30.
82. Addy M, Prayitno SW. Light microscopic and color television image analysis of the development of staining on chlorhexidine-treated surfaces. J Periodontol 1980;51:39-43.
83. Spijkervet FKL, van Saene HKF, Panders AK, et al. Effect of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis. Oral Surg Oral Med Oral Pathol 1989;67:154-61.
84. Wahlin YB. Effects of chlorhexidine mouthrinse on oral health in patients with acute leukemia. Oral Surg Oral Med Oral Pathol 1989;68:279-87.
85. Ferretti GA, Raybould TP, Brown AT. Chlorhexidine prophylaxis for chemotherapy and radiotherapy induced stomatitis: A randomised double blind trial. Oral Surg Oral Med Oral Pathol 1990;69:331-8.
86. Ferraro JM, Mattern J. Sucralfate suspension for stomatitis (letter). Drug Intell Clin Pharm 1984;18:153.
87. Adams S, Toth B, Dudley BS. Evaluation of sucralfate suspension for the treatment of stomatitis. Clin Pharmacol Ther 1985;37:178.
88. Soloman MA. Oral sucralfate suspension for mucositis (letter). N Engl J Med 1986;315:459-60.
89. Barker G, Loftus L, Cuddy P, et al. The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral surg Oral Med Oral Pathol 1991;71:288-93.
90. Azul AM. Sucralfato no tratamento da radiomucite. Rev Port Estomatol Cir Maxilofac 1993:2:231-7.
91. Pfeiffer P, Hansen O, Madsen EL, et al. A prospective pilot study on the effect of sucralfate mouth-swishing in reducing stomatitis during radiotherapy of the oral cavity. 1990; 29:471-3.
92. Tarnawski A, Hollander D, Gergely H. The mechanism of protective, therapeutic and prophylactic actions of sucralfate. Scand J Gastroenterol 1987;22:7-13.
93. Garnet W. Sucralfate - an alterntive therapy for peptic ulcer disease. Clin Pharm 1985;1:307-14.
94. Brooks WS. Sucralfate: Non-ulcer uses. Am J Gastroenterol 1985;80:206-9.
95. Matejka M, Nell A, Kment G, et al. Local benefit of prostaglandin E2 in radiochemotherapy induced oral mucositis. Br J Oral Maxillofac Surg 1990;28:89-91.
96. Labar B, Mrsic M, Pavletic Z, et al. Prostagandin E2 for prophylaxis of oral mucositis following bone marrow transplantation. Bone Marrow Transplant 1993;11:379-82.
97. Carl W, Emrich LS. Management of oral mucositis during radiation and systemic chemotherapy: A study of 98 patients. J Prosthet Dent 1991;66:361-9.
98. Theimer K, Stadler R, Isaac O. Biochemical investigations of camomile. Arzneimittelforschung (Drug Res) 1973;23:756-9.
99. Clark PI, Steven ML. Allopurinol mouthwash and 5-fluorouracil induced oral toxicity. Eur J Surg Oncol 1985;11:267-8.
100. Tsavaris N, Caragiauris P, Kosimidis P. Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes. Eur J Surg Oncol 1988;14:405-6.
101. Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil induced stomatitis. Cancer 1990;65:1879-82.
102. Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil induced stomatitis by oral cryopathy. J Clin Oncol 1991;9:449-52.
103. Cascinu S, Federli A, Federli SL, et al. Oral cooling (cryotherapy): An effective treatment for the prevention of 5-fluorouracil induced stomatitis. Eur J Cancer Oral Oncol 1994;30B:234-6.
104. Montecucco C, Caporali R, Rossi S, et al. Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 1994;37:777-8.
105. Pourreau-Schneider N, Soudry M, Franquin JC, et al. Soft-laser therapy for iatrogenic mucositis in cancer patients receiving high-dose fluorouracil: A preliminary report. J Natl Cancer Inst 1992;84:358-9.
106. Braverman B, McCarthy RJ, Ivankovich AD. Effect of helium-neon and infrared laser irradiation on wound healing in rabbits. Lasers Surg Med 1989;9:50-8.
107. Rochkind S, Rousso M, Nissan M. Systemic effects of low-power laser irradiation on the peripheral and central nervous system, cutaneous wounds and burns. Lasers Surg Med 1989;9:174-82.
108. Pourreau-Schneider N, Soudry M, Remusat M. Modifications of growth dynamics and ultrastructure after helium-neon laser treatment of human gingival fibroblasts. Quintessence Int 1989;20:887-93.
109. Karu T. Photobiology of low-power laser effects. Health Phys 1989;56:691-704.
110. Pourreau-Schneider N, Ahmed A, Soudry M. Helium-neon laser treatment transforms fibroblasts into myofibroblasts. Am J Pathol 1990;137:171-8.
111. Meunier F, Paesmans M, Autier P. Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients. Eur J Cancer Oral Oncol 1994;30B:196-9.
112. Spijkervet FK, Van Saene HK, Van Saene JJ, etal. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 1991;46:167-73.
113. De Clercq E. Antivirals for the treatment of herpes virus infections J Antimicrob Chemother 1993;32 (Suppl A):121-32.
114. Mira JG, Westcott WB, Starke EN, et al. Some factors influencing salivary function when treating with radiotherapy. Int J Radiat Oncol Biol Phys 1981;7:535-41.
115. Wolff A, Atkinson JC, Macynski AA, et al. Pretherapy interventions to modify salivary dysfunction. NCI Mongr 1990;9:87-90.
116. Risheim H, Amegerg P. Salivary stimulation by chewing gum and lozenges in rheumatic patients with xerostomia. Scand J dent Res 1993;101:40-3.
117. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
118. Fox PC, Van der Ven PF, Baum BJ, et al. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986;61:243-5.
119. LeVeque FG, Montgomery M, Potter D. et al. A muticenter, randomised, double-blind, placebo-controlled, dose-titration study or oral pilocarpine for treatment of radiation induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-31.
120. Valdez IH, Wolff A, Atkinson JC, et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71:1848-51.
121. Epstein JB, Decoteau EW, Wilkenson A. Effect of Sialor on treatment of xerostomia in Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1983;56:495-9.
122. Schiodt M, Oxholm P, Jacobsen A. Treatment of xerostomia in patients with primary Sjögren's syndrome with Sulfarlem. Scand J Rehumatol Suppl 1986;61:250-2.
123. Epstein JB, Stevenson-Moore P, Scully C. Management of xerostomia. J Can Dent Assoc 1992;58:140-3.
124. Epstein JB, Schubert MM. Synergistic effects of sialogogues in the management of xerostomia following radiation therapy. Oral Surg 1987;64:178-82.
125. Scully C. Xerostomia and its management. Lancet. 1989;i:884.
126. Greenspan D. Management of salivary dysfunction. NCI Monogr 1990;9:159-61.
127. Joyston-Bechal S, Kidd EAM. The effect of three commercially available saliva substitutes on enamel in vitro. Br Dent J 1987;163:187-90.
128. Vissnk A, S'Gravenmade EJ, Gellard TBF, et al. Rehardening properties of mucin or CMC-containing saliva substitutes on softened human enamel. Caries Res 1985;19:212-8.
129. Visch LL, S'Gravenmade EJ, Schraub RM, et al. A double blind crossover trial of CMC- or mucin-containing saliva substitutes. Int J Oral Maxillofac Surg 1986;15:395-400.
130. Levine J, Aquirre A, Hatton MN, et al. Artificial salivas: present and future. J Dent Res 1987;66:693-8.
131. Weerkamp AH, Wagner K, Vissink A, et al. Effect of the application of a mucin-based saliva substitute on the oral microflora of xerostomic patients. J Oral Pathol 1987;19:212-18.
132. Lam TCF, Stevenson ARL, Swift R. A cure for xerostomia? Free jejunal patch graft in oral reconstruction. Br J Oral Maxillofac Surg 1995;33:152-5.
133. Habel G, O'Regan B, Carter J. Free jejunal transfer in oral reconstruction. Br J Oral Maxillofac Surg 1991;29:159-63.
134. Sasaki TM, Baker HW, McConnell DB, et al. Free jejunal mucosal patch graft reconstruction. Arch Surg 1982;117:459-62.
135. Buckspan GS, Newton ED, Franklin JD, et al. Split jejunal free-tissue transfer in oropharyngoesophageal reconstruction. Plast Reconstr Surg 1986;77:717-28.
136. Simon AR, Roberts MW. Management of oral complications associated with cancer therapy in pediatric patients. J Dent Child 1991;58:384-9.
137. Porter SR, Scully C. Oral health care for special needs patients. Northwood: Science Review, 1995.
138. Meyerowitz C, Featherstone JD, Billings RJ, et al. Use of an intra-oral model to evaluate 0.05% sodium fluoride mouthrinse in radiation induced hyposalivation. J Dent Res 1991;70:894-8.
139. Joyston-Bechal S, Hayes K, Davenport E. Caries, mutans streptococci and lactobacilli in irradiated patients during a 12-month programme using chlorhexidine and fluoride. Caries Res 1992;26:384-90.
140. Van Steenberghe D, van den Eynde E, Jacobs R, et al. Effect of a lactoperoxidase containing toothpaste in radiation induced xerostomia. Int Dent J 1994;44:133-8.
141. Hastka J, Hehlmann R. Local treatment of thrombocytopenic mucosal haemorrhage. Lancet 1993;342:55.
142. Ben-Bassat I, Douer D, Ramot B. Tranexamic acid therapy in acute myeloid leukemia: Possible reduction in platelet transfusions. Eur J Haematol 1990;45:86-9.
143. Widemark G, Sagne S, Heikel P. Osteoradionecrosis of the jaws. Int J Oral Maxillofac Surg 1989;18:302-6.
144. Makkonen TA, Kiminki A, Makkonen TK, et al. Dental extractions in relation to radiation therapy of 224 patients. Int J Oral Maxillofac Surg 1987;16:56-64.
145. Beumer J, Harrison R, Sanders B, et al. Osteonecrosis: Predisposing factors and outcomes of therapy. Head Neck Surg 1984;6:819-27.
146. Yanagiya K, Takato T, Akagawa T, et al. Reconstruction of large defects that include the mandible with scapular, osteocutaneous and forearm flaps: Report of cases. J Oral Maxillofac Surg 1993;51:439-44.
147. Nakatsuka T, Narii K, Yamada A, et al. Dual free flap transfer using forearm flap for mandibular reconstruction. Head Neck 1992;14:452-8.
148. Harris M. The conservative management of osteoradionecrosis of the mandible with ultrasound therapy. Br J Oral Maxillofac Surg 1992;30:313-8.
149. Marx RE, Osteonecrosis of the jaws: A review and update. HBO Rev 1984;5:78-127.
150. Farmer JC, Shelton DL, Angelillo JD, et al. Treatment of radiation induced tissue injury by hyperbaric oxygen. Ann Otol 1987;87:707-15.
151. Fattore L, Strauss RA. Hyperbaric oxygen in the treatment of osteoradionecrosis: A review of its use and efficacy. Oral Surg Oral Med Oral Pathol 1987;63:280-6.
152. Daum REO, Negus TW. Hyperbaric oxygen in osteoradionecrosis of the mandible. J R Nav Med Serv 1988;84:51-4.
153. McKenzie MR, Wong FLW, Epstein JB, et al. Hyperbaric oxygen and postradiation osteoradionecrosis of the mandible. Eur J Cancer Oral Oncol 1993;29B:201-7.
154. Hart GB, Mainous EG. The treatment of radiation necrosis with hyperbaric oxygen. Cancer 1976;37:2580-5.
155. Giebfried JW, Lawson W, Biller HF. Complications of hyperbaric oxygen in head and neck disease. Otolaryngol Head Neck Surg 1986;94:508-12.
156. Dion MW, Hussey DH, Doornbos JF, et al. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Rad Oncol Biol Phys 1990;19:401-7.
157. Lizi EC. A case for a dental surgeon at regional radiotherapy centres. Br Dent J 1992;11:24-6.
158. Fayle SA, Duggal MS, Williams SA. Oral problems and the dentist's role in the management of paediatric oncology patients. Dent Update 1992;19:152-9.